Level B· Emerging clinical evidence with positive signalsClinical TrialPubMedOpen access

Factors affecting outcomes of intra-articular injection of autologous, culture-expanded, adipose-derived mesenchymal stem cells in knee osteoarthritis.

Park JB., Jang GY., Cho KY., Lee H., Kim KI.

Clinical Trial with a reported sample of 104 on Knee Osteoarthritis, Osteoarthritis, published in Stem Cells Transl Med (2026) — summary generated from the PubMed abstract.

Open my reading list
Level B· Emerging clinical evidence with positive signalsEvidence level of this study

Several human studies show positive signals, while research methods and sample sizes continue to develop.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Clinical Trial
Journal
Stem Cells Transl Med (2026)
Country
England
Reported sample size
104
Source database
PubMed
PMID
42184973
PMCID
PMC13200742
DOI
10.1093/stcltm/szag027
NCT
NCT04427930

Abstract (original English)

This study aims to assess the outcomes of intra-articular injection of adipose-derived mesenchymal stem cells (ADMSC) in osteoarthritis (OA) of knee joint up to 3-year follow-up and evaluate possible factors related to the outcomes. This was a prospective observational follow-up of participants from the ADMSC treatment arm of a prior phase III clinical trial. A total of 104 patients were assessed through the follow-up study for 3 years after ADMSC injection. We assessed the WOMAC and VAS for pain at 1-, 2-, and 3-year post-injection and compared with baseline values. Minimal clinically important difference (MCID) was calculated, and the proportion of patients achieving MCID was evaluated at each time point. Finally, we assessed which factors may affect the outcome. Significant improvements in WOMAC and VAS scores were observed after ADMSC injection, with these benefits sustained throughout the 1-, 2-, and 3-year follow-up. The proportion achieving MCID slightly decreased over time without statistical significance. Significant factors affecting the favorable outcomes were lower body mass index (BMI) (<25), higher baseline clinical scores up to 3 years after the injection. Other variables did not show the significant relation. Intra-articular injection of autologous, culture-expanded ADMSC in patient with knee OA was sustained improvements observed up to 3 years in terms of WOMAC

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Several human studies show positive signals, while research methods and sample sizes continue to develop.

How we grade evidence
HumansInjections, Intra-ArticularFemaleOsteoarthritis, KneeMaleMesenchymal Stem Cell TransplantationMiddle AgedMesenchymal Stem CellsTreatment OutcomeAdipose Tissue

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research